Fulcrum Therapeutics Inc (NASDAQ: FULC) flaunted slowness of -6.90% at $3.51, before settling in for the price of $3.77 at the close. Taking a more long-term approach, FULC posted a 52-week range of $2.86-$13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -1.10%. Meanwhile, its Annual Earning per share during the time was 1.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 90.17%. This publicly-traded company’s shares outstanding now amounts to $53.94 million, simultaneously with a float of $46.61 million. The organization now has a market capitalization sitting at $189.33 million. At the time of writing, stock’s 50-day Moving Average stood at $3.46, while the 200-day Moving Average is $6.95.
Fulcrum Therapeutics Inc (FULC) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Fulcrum Therapeutics Inc industry. Fulcrum Therapeutics Inc’s current insider ownership accounts for 13.58%, in contrast to 87.62% institutional ownership. According to the most recent insider trade that took place on May 07 ’24, this organization’s Principal Accounting Officer sold 236 shares at the rate of 7.76, making the entire transaction reach 1,831 in total value, affecting insider ownership by 11,571. Preceding that transaction, on Mar 08 ’24, Company’s Vice President, Finance sold 4,884 for 11.72, making the whole transaction’s value amount to 57,219. This particular insider is now the holder of 11,807 in total.
Fulcrum Therapeutics Inc (FULC) Earnings and Revenue Records
Fulcrum Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 90.17% and is forecasted to reach -1.04 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 16.40% through the next 5 years, which can be compared against the 1.09% growth it accomplished over the previous five years trading on the market.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Let’s observe the current performance indicators for Fulcrum Therapeutics Inc (FULC). It’s Quick Ratio in the last reported quarter now stands at 18.44. The Stock has managed to achieve an average true range (ATR) of 0.27. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.34.
In the same vein, FULC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.31, a figure that is expected to reach -0.28 in the next quarter, and analysts are predicting that it will be -1.04 at the market close of one year from today.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Now, what If we examine the latest scores posted by [Fulcrum Therapeutics Inc, FULC]. During the last 5-days, its volume was lower the volume of 0.98 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 68.58% While, its Average True Range was 0.28.
Raw Stochastic average of Fulcrum Therapeutics Inc (FULC) in the period of the previous 100 days is set at 8.94%, which indicates a major fall in contrast to 53.28% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 90.38% that was lower than 167.04% volatility it exhibited in the past 100-days period.
